Oppenheimer Maintains Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $285
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jay Olson has maintained an 'Outperform' rating on Madrigal Pharmaceuticals (NASDAQ:MDGL), but lowered the price target from $350 to $285.

August 09, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer has maintained an 'Outperform' rating on Madrigal Pharmaceuticals but lowered the price target from $350 to $285.
The news is directly related to Madrigal Pharmaceuticals. While the 'Outperform' rating is maintained, the lowering of the price target might indicate a potential slowdown in the company's growth or a reassessment of its valuation. This could have a neutral impact on the stock price in the short term as the positive 'Outperform' rating is balanced by the lower price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100